BCIQ Profiles

Company Profile Report
0428 PDev QTs
BioCentury & Getty Images

Product Development

April 28 Quick Takes: Brukinsa data buoy BeiGene; plus Adverum, Dynamk, Pfizer-Amplyx, Boundless Bio and Clarus   

Apr 29, 2021 | 1:56 AM GMT

Positive Phase III data for Brukinsa zanubrutinib lifted shares of BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) 9% on NASDAQ, leaving the company with a market cap of $32 billion. The Btk inhibitor showed

Read the full 573 word article

How to gain access

Continue reading with a
two-week free trial.